title: RASAL2: wrestling in the combat of Ras activation.
abstract: Oncogenic activation of Ras proteins due to missense mutations is frequently detected in human cancers but rarely in breast cancer. In this issue of Cancer Cell, McLaughlin and colleagues report that ablation of the GasGAP gene, RASAL2, is an alternative mechanism by which Ras becomes activated in breast cancer.
authors.affiliation: Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA; The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, TX 77030, USA.
authors.forename: Jia
authors.initials: J
authors.lastname: Shen
authors.forename: Yan
authors.initials: Y
authors.lastname: Wang
authors.forename: Mien-Chie
authors.initials: MC
authors.lastname: Hung
mesh_terms: D000818:Animals; D002352:Carrier Proteins / Q000235:genetics*; D005260:Female; D020690:GTPase-Activating Proteins; D006801:Humans; D009369:Neoplasms / Q000235:genetics* / Q000473:pathology*; D025521:Tumor Suppressor Proteins / Q000235:genetics*; D020703:ras GTPase-Activating Proteins / Q000235:genetics*
chemical_list: D002352:Carrier Proteins; D020690:GTPase-Activating Proteins; C576391:RASAL2 protein, human; D025521:Tumor Suppressor Proteins; D020703:ras GTPase-Activating Proteins